Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Market Closed 03-28 16:00:00 EDT

0.5705

+0.2229

+64.13%

盘后0.5749

+0.0044+0.77%

19:59 EDT

High0.7000	Low0.5100	Vol405.86M
Open0.6548	D1 Closing0.3476	Amplitude54.66%
Mkt Cap206.23M	Tradable Cap103.79M	Total Shares361.49M
T/O251.89M	T/O Rate223.09%	Tradable Shares181.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":0.5705,"timestamp":1743192000000,"preClose":0.3476,"halted":0,"volume":405857725,"hourTrading":{"tag":"盘后","latestPrice":0.5749,"preClose":0.5705,"latestTime":"19:59 EDT","volume":5495702,"amount":3150662.801359,"timestamp":1743206390733},"delay":0,"floatShares":181924793,"shares":361492295,"eps":-0.626198,"marketStatus":"Market Closed","change":0.2229,"latestTime":"03-28 16:00:00 EDT","open":0.6548,"high":0.7,"low":0.51,"amount":251891416.6866825,"amplitude":0.546605,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.626198,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":0.3476,"preHourTrading":{"tag":"盘前","latestPrice":0.655,"preClose":0.3476,"latestTime":"09:29 EDT","volume":56553481,"amount":37074443.1843283,"timestamp":1743168599999},"postHourTrading":{"tag":"盘后","latestPrice":0.5749,"preClose":0.5705,"latestTime":"19:59 EDT","volume":5495702,"amount":3150662.801359,"timestamp":1743206390733},"volumeRatio":109.55475719660392,"optionData":{"bulkOrders":[{"symbol":"LXRX","call":true,"expireDate":1752811200000,"strike":"1.0","timestamp":1743190099511,"price":0.15,"volume":1500,"amount":22500,"type":"+"}]},"impliedVol":2.7394,"impliedVolPercentile":0.884},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"2523686722","title":"BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2523686722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523686722?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:47","pubTimestamp":1743184057,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, WolfspeedEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL6N3QB0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","GME","AGX","ENPH","NVDY","DTC","NVDS","STSS","WRB","NVDX","AIR","NVD","BEAM","LDOS","NVD2.UK","NVDD","SNVD.UK","3NVD.UK","NVIW.SI","NVDU","ECX","LXRX","2NVD.UK","OXM","CPT","CVAC","NVD3.UK","ON","LUV","SGHC","MIST","NEM","LGMK","NVDS.UK","PTCT","AU","XPO","GHLD","WOLF","X"],"gpt_icon":1},{"id":"2522501104","title":"Lexicon Pharmaceuticals Shares up 65% on Licensing Deal With Novo Nordisk for Obesity Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522501104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522501104?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:13","pubTimestamp":1743174807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB1BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2522503339","title":"Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2522503339","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522503339?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 22:09","pubTimestamp":1743170940,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.Shares of Lexicon, based in The Woodlands, Texas, were recently changing hands at 60.4 cents, up 74%.Lexicon said the agreement gives Novo Nordisk an exclusive, worldwide license to develop, manufacture and commercialize LX9851, which is in development for the treatment of obesity and associated cardiometabolic disorders.Lexicon said it will receive an upfront payment of $45 million from Novo Nordisk, which makes the blockbuster weight-loss drugs Ozempic and Wegovy.Lexicon is also eligible for up to $960 million in development, regulatory and sales milestone payments, along with royalties on sales of LX9851.Lexicon last year said preclinical data show that LX9851 significantly reduced weight, food intake and fat mass in mice when combined with semaglutide, the key ingredient in Ozempic and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","LXRX","BK4139"],"gpt_icon":1},{"id":"2522573061","title":"BUZZ-Lexicon surges on licensing deal with Novo Nordisk for obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573061?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:06","pubTimestamp":1743163570,"startTime":"0","endTime":"0","summary":"BUZZ-Lexicon surges on licensing deal with Novo Nordisk for obesity drug ** Shares of drug developer Lexicon Pharmaceuticals LXRX.O jump 108% to 72 cents premarket ** LXRX says it has entered into an ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB0WV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2522573982","title":"Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573982","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573982?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:00","pubTimestamp":1743163226,"startTime":"0","endTime":"0","summary":"UPDATE 3-Novo Nordisk to license obesity drug from Lexicon in up to $1 billion dealAdds analyst comment in paragraph 9By Sneha  S K. Novo Nordisk NOVOb.CO is licensing Lexicon Pharmaceuticals' LXRX.O experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of its weight-loss treatments.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"4a641e4e4a3f19d0d6240caa73da3835","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB0WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","03933","BK1191","LXRX"],"gpt_icon":0},{"id":"2522578447","title":"BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578447","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578447?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:49","pubTimestamp":1743162596,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851March 28 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUAC1H3XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2522200455","title":"Lexicon Pharmaceuticals Shares up 70% Premarket on Licensing Deal With Novo Nordisk for Obesity Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522200455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522200455?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:40","pubTimestamp":1743162049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2522224573","title":"Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2522224573","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522224573?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments. THE WOODLANDS, Texas, March 28, 2025  -- Lexicon Pharmaceuticals, Inc.  today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing agreed upon Investigational New Drug  application-enabling activities for LX9851. Novo Nordisk will be responsible for filing the IND, all further development, manufacturing and commercialization of LX9851.Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-exclusive-license-113000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","LXRX","BK4599","BK4585","LU0154236417.USD","BK4007","LU1093756168.USD","NVO","BK4532"],"gpt_icon":1},{"id":"2522359769","title":"Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522359769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522359769?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 02:55","pubTimestamp":1743015359,"startTime":"0","endTime":"0","summary":"The Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) share price has fared very poorly over the last month, falling by a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/investors-dont-see-light-at-end-of-lexicon-pharmaceuticals-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","BK4139","IE00B64PRP62.GBP","PSQ","LU2095319765.USD","NQmain","TSYW.SI","BK4585","QLD","NVIW.SI","IE00BGHQF748.EUR","BK4211",".IXIC","BK4112","BK4588","LXRX","IE00BKPKM429.USD","ISBC","LU2210149790.SGD","NDAQ","USAW.SI","USJW.SI","IE00B3QW5Z07.USD","MNQmain","SQQQ","QID","LU2210150020.SGD"],"gpt_icon":1},{"id":"2518762071","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO), Johnson & Johnson (JNJ) and Lexicon Pharmaceuticals (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518762071?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 15:31","pubTimestamp":1741678265,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BridgeBio Pharma (BBIO – Research Report), Johnson...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bridgebio-pharma-bbio-johnson-johnson-jnj-and-lexicon-pharmaceuticals-lxrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bridgebio-pharma-bbio-johnson-johnson-jnj-and-lexicon-pharmaceuticals-lxrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1066053197.SGD","LU1778281490.HKD","LU1280957306.USD","LU0882574055.USD","LU1674673691.USD","LU1718418525.SGD","BK4504","SG9999002232.USD","LU1162221912.USD","BK4007","IE0034235303.USD","BK4534","LU0792757196.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1894683348.USD","BK4585","JNJ","LU0098860793.USD","BK4581","BK4550","IE00B3PB1722.GBP","IE00BJT1NW94.SGD","LU1732800096.USD","LU2430703095.HKD","IE00BDGV0183.EUR","IE0002141913.USD","LU1261432733.SGD","LU0795875086.SGD","IE00BVYPNV92.GBP","LU0345769631.USD","LU1267930813.SGD","LU1244550577.SGD","BBIO","LU0114720955.EUR","BK4533","LU2129689514.USD","LU1059921491.USD","LU0234572021.USD","LU2430703251.USD","LXRX","LU1914381329.SGD","BK4559","LU0889566641.SGD","IE00B19Z3B42.SGD","LU0345770308.USD","BK4139","LU1935042991.SGD","HCSG","LU0234570918.USD"],"gpt_icon":0},{"id":"2518477001","title":"Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518477001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518477001?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 14:00","pubTimestamp":1741500059,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) has disclosed a new risk, in the Capital Markets category. Lexicon Pharmaceuticals faces significant business risks ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-faces-supply-chain-risks-amidst-changing-trade-policies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-faces-supply-chain-risks-amidst-changing-trade-policies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2517493411","title":"Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2517493411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517493411?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 08:19","pubTimestamp":1741393154,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (($LXRX)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for Lexicon ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-mixed-earnings-call-achievements-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-mixed-earnings-call-achievements-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX"],"gpt_icon":0},{"id":"2517437582","title":"Lexicon Pharma Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437582","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517437582?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 23:51","pubTimestamp":1741362660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 10:51 ET (15:51 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2517438278","title":"Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438278","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438278?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:30","pubTimestamp":1741354200,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, March  07, 2025  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038933/0/en/Lexicon-Pharmaceuticals-to-Present-at-the-Leerink-Partners-Global-Healthcare-Conference-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BK4137","LXRX","BK4139"],"gpt_icon":0},{"id":"2517057484","title":"Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517057484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517057484?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:12","pubTimestamp":1741349520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 07:12 ET (12:12 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2517048188","title":"Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517048188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517048188?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:51","pubTimestamp":1741348303,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on VYNE Therapeutics (VYNE – Research Report), Lexico...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-lexicon-pharmaceuticals-lxrx-and-xtant-medical-holdings-xtnt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-lexicon-pharmaceuticals-lxrx-and-xtant-medical-holdings-xtnt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE","BK4137","BK4198","LXRX","HCSG","BK4139","XTNT","BK4007"],"gpt_icon":0},{"id":"2517907176","title":"Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517907176","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517907176?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 15:17","pubTimestamp":1741331840,"startTime":"0","endTime":"0","summary":"Cash Equivalents and Short-term Investments: $238 million as of December 31, 2024, compared to $170 million as of December 30, 2023.Revenue: $26.6 million in Q4 2024 and $31.1 million for the full year 2024.MEA Revenue: $1.7 million in Q4 2024 and $6 million for the full year 2024.Upfront Payment: $25 million received from the Vatrice licensing agreement.Research and Development Expenses: $26.7 million in Q4 2024, up from $14.8 million in Q4 2023; $84.5 million for the full year 2024.Selling, General and Administrative Expenses: $32.3 million in Q4 2024, comparable to $32.6 million in Q4 2023; $143.1 million for the full year 2024, up from $114 million in 2023.Net Loss: $33.8 million or $0.09 per share in Q4 2024, compared to $49.8 million or $0.20 per share in Q4 2023; $200.4 million or $0.32 per share for the full year 2024, compared to $177.1 million or $0.80 per share in 2023.Lexicon Pharmaceuticals Inc  ceased all promotional efforts for MEPA in the US due to a challenging market ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-inc-lxrx-q4-071720592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXRX"],"gpt_icon":0},{"id":"2517126981","title":"Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2517126981","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517126981?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 12:26","pubTimestamp":1741321560,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals ( ($LXRX) ) has released its Q4 earnings. Here is a breakdown of the information Lexicon Pharmaceuticals presented to its i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-advances-pipeline-amid-financial-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-advances-pipeline-amid-financial-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2517142110","title":"Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517142110","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517142110?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 06:10","pubTimestamp":1741299003,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals  came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.18%. A quarter ago, it was expected that this drugmaker would post a loss of $0.17 per share when it actually produced a loss of $0.18, delivering a surprise of -5.88%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Lexicon , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $26.55 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 215.37%. This compares to year-ago revenues of $0.7 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-lxrx-reports-q4-221003063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXRX"],"gpt_icon":0},{"id":"2517116418","title":"Lexicon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517116418","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517116418?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 06:01","pubTimestamp":1741298474,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryLexicon Pharmaceuticals Inc LXRX.OQ reported a quarterly adjusted loss of 9 cents per share for the quar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL5N3PP2HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":0.5708},{"period":"1month","weight":-0.1926},{"period":"3month","weight":-0.2623},{"period":"6month","weight":-0.6434},{"period":"1year","weight":-0.7623},{"period":"ytd","weight":-0.2275}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.52,"avgChangeRate":0.042172},{"month":2,"riseRate":0.4,"avgChangeRate":-0.059177},{"month":3,"riseRate":0.48,"avgChangeRate":-0.013152},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.011119},{"month":5,"riseRate":0.52,"avgChangeRate":0.035958},{"month":6,"riseRate":0.64,"avgChangeRate":0.119795},{"month":7,"riseRate":0.48,"avgChangeRate":0.017089},{"month":8,"riseRate":0.24,"avgChangeRate":-0.027412},{"month":9,"riseRate":0.32,"avgChangeRate":0.002483},{"month":10,"riseRate":0.52,"avgChangeRate":-0.007629},{"month":11,"riseRate":0.36,"avgChangeRate":-0.04494},{"month":12,"riseRate":0.48,"avgChangeRate":0.072476}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}